Outcome of induction cohorts
Cohort . | Treatment . | No. . | ANC to 1.0 × 109/L, d median (range) . | Platelets to 100 × 109/L, d median (range) . | Grade 3 or 4 hepatotoxicity . | Deaths . | CR course 1, N (%) . |
|---|---|---|---|---|---|---|---|
| 1 | H-DAT + 3 mg/m2 GO | 22 | 30.5 (23-41) | 35 (26-48) | 6 | 2 | 20 (91) |
| 2 | H-DAT + 6 mg/m2 GO | 9 | 24 (22-43) | 36 (30-43) | 5 | 1 | 8 (89) |
| 3 | H-DAT + 3 mg/m2 GO and H-DAT + 3 mg/m2 GO | 15 | 33 (23-50)* | 50 (35-68)*† | 5* | 5* | NA |
| 4 | S-DAT + 3 mg/m2 GO | 10 | 26 (21-54) | 27 (22-34) | 4‡ | 2 | 6 (60) |
| 5 | S-DA + 3 mg/m2 GO | 8 | 28 (19-35) | 25 (21-41) | 2 | 0 | 8 (100) |
| 6 | FLAG-Ida + 3 mg/m2 GO | 15 | 24 (22-38) | 26 (21-60) | 3 | 1 | 13 (87) |
Cohort . | Treatment . | No. . | ANC to 1.0 × 109/L, d median (range) . | Platelets to 100 × 109/L, d median (range) . | Grade 3 or 4 hepatotoxicity . | Deaths . | CR course 1, N (%) . |
|---|---|---|---|---|---|---|---|
| 1 | H-DAT + 3 mg/m2 GO | 22 | 30.5 (23-41) | 35 (26-48) | 6 | 2 | 20 (91) |
| 2 | H-DAT + 6 mg/m2 GO | 9 | 24 (22-43) | 36 (30-43) | 5 | 1 | 8 (89) |
| 3 | H-DAT + 3 mg/m2 GO and H-DAT + 3 mg/m2 GO | 15 | 33 (23-50)* | 50 (35-68)*† | 5* | 5* | NA |
| 4 | S-DAT + 3 mg/m2 GO | 10 | 26 (21-54) | 27 (22-34) | 4‡ | 2 | 6 (60) |
| 5 | S-DA + 3 mg/m2 GO | 8 | 28 (19-35) | 25 (21-41) | 2 | 0 | 8 (100) |
| 6 | FLAG-Ida + 3 mg/m2 GO | 15 | 24 (22-38) | 26 (21-60) | 3 | 1 | 13 (87) |